Breast Cancer

World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.

After a false positive breast cancer screening result, women may be reluctant to participate in future screening, a topic that could benefit from the primary care touch.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

After a false positive outcome on screening mammography, a short interval call back for repeat imaging was a significant deterrent to future screening.

The most common harm associated with breast cancer screening is a false positive finding; this UC Davis expert wanted to know more about how women respond.

Breast cancer will claim the lives of more than 42 000 women in 2024. The primary care clinician's role as advocate for screening mammography can not be overemphasized.

Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.

Your daily dose of the clinical news you may have missed.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Over 4 million cancer deaths have been reverted since 1991, but new cancer cases are estimated to reach over 2 million, according to new data from an annual American Cancer Society report.

Your daily dose of the clinical news you may have missed.

In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.

Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.

The lower recommended starting age for screening reflects rising cancer diagnoses among younger women and persistently high mortality rates among Black women.

A combination of outreach measures tailored to the needs of rural Midwest women increased recommended screenings by as much as 6-fold.

Race- and ethnicity-specific starting ages for screening would help prevent early breast cancer mortality among Black women, according to authors of a new study.

Breast cancer survivors rely on their primary care clinicians as resources integral to their recovery and return to optimal function. Physiatrist Sean Smith, MD, offers details.

In this Medical News Minute, Dr Bobby Lazzara reviews a study on the influence of media bias on far-reaching medical decisions in the general public.

October is Breast Cancer Awareness Month and Pregnancy and Infant Loss Awareness Month. Check here for a brief roundup of the latest women’s health news.

Women who exercise may lower their risk, although those who have received hormone replacement therapy may not get the same benefit. Organized programs can help.

Outcomes are poorer for young women and others with breast cancer when blood sugar levels reflect prediabetes or undiagnosed diabetes. What can you do?

We see survivors of breast cancer in primary care practice every day. Here, 8 guideline recommendations to help you ensure their continued health.

This case highlights medication errors that can result from drug interactions noted with the use of tamoxifen or other chemotherapeutic agents.

ROCKVILLE, Md. -- The FDA has approved the osteoporosis drug raloxifene (Evista) for prevention of invasive breast cancer in high-risk or osteoporotic postmenopausal women.

A 51-year-old woman has had a progressiverash on the trunk, proximalarms, and legs for 2 weeks, followingthe latest round of chemotherapy forbreast cancer. Around the time thatthe rash erupted, she was also takinglevofloxacin for a productive cough.Cutaneous lupus erythematosus wasdiagnosed years ago, but she hasbeen disease-free for the past 5 years.Chemotherapy is being withheldpending diagnosis of the rash.

A 73-year-old man is admittedto the hospital with pulmonary tuberculosis.A 3-drug fixed combination-isoniazid, rifampicin, and pyrazinamide-and ethambutol are given.Within an hour, a global urticarialrash erupts (A and B).